AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02399826 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Offloading
Description: Provision of an offloading cam walker or cast boot, may also convert to total contact cast and add felt or foam to supplement
Study NCT02399826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dressing Application
Description: Application of a non adherent dressing, and a multi-layer compression dressing
Study NCT02626546 — intervention group
Intervention type: PROCEDURE
Intervention: Major surgical procedure
Description: observation of postoperative outcomes
Study NCT00996307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: 3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
Study NCT00996307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: 7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
Study NCT00996307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: 15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
Study NCT00996307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: 7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
Study NCT02364245 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditional OT(60 Mins)
Description: Receive Traditional Occupational Therapy training for 60 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
Study NCT00391053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Inactivated, Split-Virion Influenza Vaccine
Description: 0.5 mL, IM
Study NCT00391053 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated, Split-Virion Influenza Vaccine
Description: 0.5 mL, IM
Study NCT02850224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing to elicit PCO in pediatrics
Description: A motivational interviewing style webinar. Physicians watch the webinar, incorporate communication techniques.
Study NCT03528655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Decision aid is a tool that helps pregnant women become involved in decision making on choosing rooming-in or separation care. Decision aid provides information about the options and outcomes, and by clarifying personal values.
Study NCT04667676 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupoint TENS
Description: TENS was applied bilaterally on acupoint Ex-B1, 4Hz frequency, and 200 μs pulse width and intensity was set at the best highest tolerable intensity by the patient sensitivity without a sensation of discomfort for 45 minutes, three times/week for four weeks
Study NCT04667676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupoint TENS
Description: TENS was applied bilaterally on acupoint Ex-B1, 4Hz frequency, and 200 μs pulse width and intensity was set at the best highest tolerable intensity by the patient sensitivity without a sensation of discomfort for 45 minutes, three times/week for four weeks
Study NCT00335283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole Tablet
Description: 40 mg bid x 16 weeks
Study NCT00335283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PH and impedence testing
Description: 24 hour ph monitoring
Study NCT00335283 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PH and impedence testing
Description: 24 hour ph monitoring
Study NCT00335283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manometry
Description: done prior to pH probe to measure length of esophagus
Study NCT00335283 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: manometry
Description: done prior to pH probe to measure length of esophagus
Study NCT00335283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole
Description: 40mg bid
Study NCT00335283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet bid
Study NCT04469023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)
Study NCT03049579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weiquan Yogurt with probiotics
Description: 150 ml daily consumption for a total of 12 weeks
Study NCT00732654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Protein Extract Immunotherapy goal of 4mg/day
Description: Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
Study NCT01404078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double dose Polycap
Description: 2 Capsules of low strength polycap with 30mEq of Potassium
Study NCT04095312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revo-i robotic surgery system (Model MSR-5100)
Description: for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general HBP surgery
Study NCT04095312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revo-i robotic surgery system (Model MSR-5100)
Description: for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general Uro surgery
Study NCT00732654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Protein Extract Immunotherapy goal of 7mg/day
Description: Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
Study NCT00732654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Powder Immunotherapy goal dose 2000 mg/day
Description: Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
Study NCT04095312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revo-i robotic surgery system (Model MSR-5100)
Description: for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general colorectal surgery
Study NCT03803930 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Using 22G FNB, the first pass is SP
Description: Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
Study NCT03803930 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Using 22G FNB, the first pass is MWST
Description: Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
Study NCT03803930 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Using 20G FNB, the first pass is SP
Description: Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
Study NCT03803930 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Using 20G FNB, the first pass is MWST
Description: Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.technique-slow pull.
Study NCT02757573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypercarbia
Description: PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
Study NCT02383810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elsiglutide
Study NCT00732654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Powder Immunotherapy goal dose 1000mg/day
Description: Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
Study NCT03432208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GI consult
Study NCT03432208 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GI consult
Study NCT03582839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROTECT+
Description: The early intervention PROTECT+ consists of a cognitive-behavioral 4-session brief-protocol (100 minutes) and targets empirically identified risk factors of (I)GD/IUD, i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
Study NCT02940028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: Brief expressive writing intervention
Study NCT02940028 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control writing
Description: Brief fact-based writing exercise.
Study NCT02602704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bazedoxifene
Description: Bazedoxifene 20mg/day (Viviant) for 48 weeks
Study NCT02602704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium/Vit D
Description: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day) for 48 weeks
Study NCT02663115 — intervention group
Intervention type: OTHER
Intervention: Biopsy of the diaphragmatic muscle
Study NCT02663115 — intervention group
Intervention type: OTHER
Intervention: Skeletal muscle biopsy
Study NCT04537572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: comparison of sample collection methods
Description: Samples will be collected via finger-stick, saliva collection, and traditional phlebotomy to determine effects on COVID-19 antibody test results.
Study NCT01759628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.pylori eradication
Description: The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
Study NCT03846076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioral therapy
Study NCT02030860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).
Study NCT02030860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abraxane
Description: Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
Study NCT02030860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
Study NCT02030860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
Study NCT02030860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
Study NCT00664157 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Facial expression recognition of emotion
Description: Facial expression recognition test Lexical decisiontest
Study NCT00664157 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Facial expression recognition of emotion
Description: Facial expression recognition test Lexical decision test
Study NCT05764811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin 100mg
Description: 100 mg daily for a month
Study NCT02912741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanish xt Extended Contact Varnish
Description: resin modified glass- ionomer cement varnish applied as a thin layer coating and cured
Study NCT02912741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: resin infiltration
Description: low viscous light cure resin applied in layers and cured
Study NCT00431223 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive remediation therapy
Description: 36 sessions of computerized cognitive skills training over a 12 week duration. 7 patients were assigned to cognitive remediation therapy or CRT Group.
Study NCT02668055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TB4
Description: Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells stick in the wound surface
Study NCT01899040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neuromodulation for episodic migraine headache
Study NCT01899040 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: neuromodulation for episodic migraine headache
Study NCT02253160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra Optia CMNC
Description: The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.
Study NCT02253160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COBE Spectra MNC
Description: It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.
Study NCT02253160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.
Study NCT05006391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-Coaching (Online) Community-Based Exercise
Description: PHASE 1-Intervention Phase (6 months): Participants will engage in an individual tailored home-based exercise program involving aerobic, resistance, balance and flexibility training \~60min, 3 times per week for 24 weeks. Intervention will include: Component 1) biweekly 60 min personal online coaching with a certified trainer from the YMCA (13 sessions) who will monitor and progress exercise intensity; Component 2) weekly online group-based exercise classes \~60 min each led by a trainer at YMCA; Component 3) monthly online evidence-based self-management education sessions focused on topics related to self-management and health, and physical activity living with HIV; and Component 4) a wireless physical activity monitor (WPAM) to self-monitor steps, distance, calories burned, and active minutes.~PHASE 2: Post-Intervention (6 months): Participants will be encouraged to continue with unsupervised home / outdoor-based exercise 3 times per week and to continue using their WPAM throughout.
Study NCT02565862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study NCT03801486 — intervention group
Intervention type: OTHER
Intervention: Experimental: Sprouted Chickpea Flour
Description: 255g of pasta with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
Study NCT03801486 — intervention group
Intervention type: OTHER
Intervention: Control: Semolina Flour
Description: 255g of pasta with 100% semolina flour (SEM100) with butter.
Study NCT01845493 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alpha Sprout Homogenate
Description: Alpha Sprout Homogenate
Study NCT01845493 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane Homogenate
Description: Active
Study NCT02565862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT02565862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT00998985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 10, 30, 50, 100, 200, 400, 600 or 800 mg Grazoprevir tablets, orally, once a day for 7 days
Study NCT00998985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet, orally, once a day for 7 days
Study NCT03550456 — intervention group
Intervention type: OTHER
Intervention: ECC
Description: Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
Study NCT04168905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AOTI Inc. TWO2 topical oxygen therapy equipment
Description: Patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
Study NCT04168905 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AOTI Inc. TWO2 topical oxygen therapy equipment
Description: Patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
Study NCT01700140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB D-0701
Description: Study drug patches \[Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch\] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
Study NCT01700140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
Study NCT03550456 — intervention group
Intervention type: OTHER
Intervention: ECC with CLE
Description: Continuous Laryngoscopy is endoscopy of the larynx used to obtain a view of laryngeal obstruction during exercise.
Study NCT03550456 — intervention group
Intervention type: OTHER
Intervention: Speech therapy
Description: Patients with diagnosis of EILO will be sent to a speech therapist for at least 6 training sessions.
Study NCT01700140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
Study NCT00102804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenous (IV) administration, every (q) 21 days, until disease progression
Study NCT00102804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV administration, q 21 days
Study NCT00102804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
Study NCT00102804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
Study NCT02339441 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.
Study NCT02339441 — intervention group
Intervention type: DRUG
Intervention: Mycophenolate mofetil
Description: Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study,recommended dose 500 mg twice daily for 2 weeks increasing to 1gm twice daily.
Study NCT02339441 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.
Study NCT04275492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)
Description: Praxol hydrochloride sustained release tablets, 0.375mg/ tablet, are manufactured by hongguanbio pharmaceutical co., LTD
Study NCT04275492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)
Description: Siforl® is produced by Boehringer Ingelheim International Gmbh
Study NCT01638676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib (960 mg PO daily) in patients with unresectable BRAFV600E positive Stage IIIC and Stage IV melanoma